表紙:オンコロジー向け精密医療の世界市場 - 産業規模、シェア、動向、機会、予測:エコシステム別、用途別、地域別(2017年~2027年)
市場調査レポート
商品コード
1152251

オンコロジー向け精密医療の世界市場 - 産業規模、シェア、動向、機会、予測:エコシステム別、用途別、地域別(2017年~2027年)

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 By Ecosystem, Precision Diagnostics, Precision Therapeutics, Applied Sciences, Hematological Malignancies, & Region

出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

オンコロジー向け精密医療の世界市場 - 産業規模、シェア、動向、機会、予測:エコシステム別、用途別、地域別(2017年~2027年)
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のオンコロジー向け精密医療の市場規模は、予測期間中の2023年~2027年に目覚ましいCAGRで成長を遂げると予測されています。

がん有病率の増加や臨床試験の治療対象拡大により、オンコロジー向け精密医療の需要が高まっていることが、市場成長を後押ししています。また、高齢者人口における慢性疾患のリスク増大が市場成長を牽引し、標的化遺伝子療法の利用拡大が市場成長を促進すると期待されます。

当レポートでは、世界のオンコロジー向け精密医療市場について調査分析し、セグメント別・地域別の市場規模・シェア予測、市場力学、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のオンコロジー向け精密医療市場に与える影響

第5章 VOC(顧客の声)

  • オンコロジー向け精密医療への関心
  • がん有病率:ジェンダー別
  • がん有病率:年齢層別
  • がん有病率:地域別
  • オンコロジーで精密医療を使用する利点

第6章 臨床試験分析

第7章 特許分析

第8章 世界のオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別(精密診断、精密治療、応用科学、デジタルヘルス、情報技術)
    • 用途別(固形腫瘍と血液悪性腫瘍)
    • 地域別
    • 企業別(2021年)
  • 製品市場マップ

第9章 北米のオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別
    • 用途別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第10章 欧州のオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別
    • 用途別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第11章 アジア太平洋のオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別
    • 用途別
    • 国別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第12章 南米のオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別
    • 用途別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第13章 中東・アフリカのオンコロジー向け精密医療市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • エコシステム別
    • 用途別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第14章 市場力学

  • 促進要因
  • 課題

第15章 市場の動向と開発

第16章 SWOT分析:世界のオンコロジー向け精密医療市場

第17章 競合情勢

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Danaher Corporation
  • Abbott Laboratories, Inc.
  • Quest Diagnostics Inc
  • Eurofins Genomics LLC
  • Laboratory Corporation of America Holdings
  • Thermos Fischer Scientific, Inc.
  • bioMerieux SA

第18章 戦略的提言

目次
Product Code: 10709

The global oncology precision medicine market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Precision medicine represent the medical approach for the prevention of disease and diagnosis which is based on genetic, environmental, and behavioural variability. It helps in illnesses susceptibility prediction, diseases diagnosis, and progression, as well as medicine prescription. It assists in taking healthcare related decisions, improving quality care, and declining inefficiencies due to the trial-and-error is also augmenting the market growth. Precision medicine is widely utilized to diagnose the chromosomal abnormalities in the foetus and cancer and works for therapy for chronic diseases. The escalating demand of oncology precision medicine methods owing to the growing prevalence of cancer and the expanding number of treatment candidates in clinical trials are fueling the growth of the market.

Increasing Risk of Chronic Diseases in Geriatric Population Drives the Market Growth

Most cancer diagnoses occur in adults over the age of 65 years which demands the accurate treatment plan for this age group. Several oncologists use recommended and available geriatric assessments to help in evaluating older patients and guide their cancer treatment planning. The concept of precision medicine extends beyond tumour-specific markers to incorporate host factors that are assessed as part of a routine geriatric assessment. Oncologists are always careful to stage the cancer in creating cancer treatment plans by giving the importance of staging the aging to ensure that cancer treatments are personalized to as per the patient condition. Assessing the health status of older adults is as important and essential to optimizing treatment as assessing tumour biology and should be included alongside other precision medicine initiatives. I applaud the authors on a well-written and insightful article on implementing geriatric assessment and encourage oncology providers to use geriatric assessments in the routine care of their older patients and to apply this knowledge to individualize their care of this growing and vulnerable population.

Rise in Use of Targeted Gene Therapy is Expected to Propel the Market Growth

Gene therapy considered as one of the most lucrative markets for precision medicine organizations. Genome sequencing is an unavoidable stage of gene therapy, the extensive investments that are being made in this field drives the growth of the precision medicine market. The increase in number of cancers is escalating the demand for gene therapy as an effective personalized treatment choice across the globe. The significant growth in the number of patients necessitates gene therapy as a potential treatment approach addressing the increasing global burden of the disease. With this, the expanding adoption of emerging genomic technologies, including NGS and high-density microarray, along with the several government initiatives is propelling the market growth.

Market Segmentation

The global oncology precision medicine market is segmented into ecosystem, application, and regional distribution. Based on the ecosystem, the market is divided into precision diagnostics, precision therapeutics, applied sciences, digital health, and information technology. Based on the precision diagnostics, the market is bifurcated into molecular diagnostics and medical imaging. Based on the precision therapeutics, the market is divided into clinical trials, cell therapy, drug discovery & research, gene therapy. Based on the applied sciences, the market is divided into genomics, pharmacogenomics, others. Based on the digital health, and information technology, the market is divided into clinical decision support systems (CDSS), big data analytics, genomics informatics, in-silico informatics, others. Based on application, the market is segmented into insect scouting, crop disease scouting, weed scouting, others. Based on application, the market is bifurcated into solid tumor and hematological malignancies. Based on solid tumor, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, others. Based on hematological malignancies, the market is divided into hodgkin lymphoma, non-hodgkin lymphoma, leukemia, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, F. Hoffmann-La Roche AG, Merck & Co., Inc., Danaher Corporation, Abbott Laboratories, Inc., Quest Diagnostics Inc, Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., bioMerieux SA are the leading market players contributing the growth of the global oncology precision medicine market.

Report Scope:

In this report, global oncology precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Oncology Precision Medicine Market, By Ecosystem:

  • Precision Diagnostics
  • Precision Therapeutics
  • Applied Sciences
  • Digital Health
  • Information Technology

Oncology Precision Medicine Market, By Precision Diagnostics:

  • Molecular Diagnostics
  • Medical Imaging

Oncology Precision Medicine Market, By Precision Therapeutics:

  • Clinical Trials
  • Cell Therapy
  • Drug Discovery & Research
  • Gene Therapy

Oncology Precision Medicine Market, By Applied Sciences:

  • Genomics
  • Pharmacogenomics
  • Others

Oncology Precision Medicine Digital Health, and Information Technology:

  • Clinical Decision Support Systems (CDSS)
  • Big Data Analytics
  • Genomics Informatics
  • In-Silico Informatics
  • Others

Oncology Precision Medicine Market, By Application:

  • Solid Tumor
  • Hematological Malignancies

Oncology Precision Medicine Market, By Solid Tumor:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

Oncology Precision Medicine Market, By Hematological Malignancies:

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Leukemia
  • Others

Oncology Precision Medicine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Malaysia
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Poland
    • Denmark
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Peru
    • Chile
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Iraq
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global oncology precision medicine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Oncology Precision Medicine Market

5. Voice of Customer

  • 5.1. Oncology Precision Medicine Awareness
  • 5.2. Cancer Prevalence, By Gender
  • 5.3. Cancer Prevalence, By Age Group
  • 5.4. Cancer Prevalence, Region
  • 5.5. Benefits of Using Precision Medicine in Oncology

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Oncology Precision Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 8.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 8.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 8.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 8.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 8.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 8.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 8.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 8.2.3. By Region
    • 8.2.4. By Company (2021)
  • 8.3. Product Market Map

9. North America Oncology Precision Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 9.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 9.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 9.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 9.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 9.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 9.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 9.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Oncology Precision Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Ecosystem
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Oncology Precision Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Ecosystem
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Oncology Precision Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Ecosystem
        • 9.3.3.2.2. By Application

10. Europe Oncology Precision Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 10.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 10.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 10.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 10.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 10.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 10.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 10.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 10.2.3. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Oncology Precision Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Ecosystem
        • 10.3.1.2.2. By Application
    • 10.3.2. Germany Oncology Precision Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Ecosystem
        • 10.3.2.2.2. By Application
    • 10.3.3. United Kingdom Oncology Precision Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Ecosystem
        • 10.3.3.2.2. By Application
    • 10.3.4. Italy Oncology Precision Medicine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Ecosystem
        • 10.3.4.2.2. By Application
    • 10.3.5. Spain Oncology Precision Medicine Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Ecosystem
        • 10.3.5.2.2. By Application

11. Asia-Pacific Oncology Precision Medicine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 11.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 11.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 11.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 11.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 11.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 11.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 11.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 11.2.3. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Oncology Precision Medicine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Ecosystem
        • 11.3.1.2.2. By Application
    • 11.3.2. India Oncology Precision Medicine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Ecosystem
        • 11.3.2.2.2. By Application
    • 11.3.3. South Korea Oncology Precision Medicine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Ecosystem
        • 11.3.3.2.2. By Application
    • 11.3.4. Japan Oncology Precision Medicine Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Ecosystem
        • 11.3.4.2.2. By Application
    • 11.3.5. Australia Oncology Precision Medicine Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Ecosystem
        • 11.3.5.2.2. By Application

12. South America Oncology Precision Medicine Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 12.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 12.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 12.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 12.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 12.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 12.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 12.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 12.2.3. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Oncology Precision Medicine Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Ecosystem
        • 12.3.1.2.2. By Application
    • 12.3.2. Argentina Oncology Precision Medicine Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Ecosystem
        • 12.3.2.2.2. By Application
    • 12.3.3. Colombia Oncology Precision Medicine Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Ecosystem
        • 12.3.3.2.2. By Application

13. Middle East and Africa Oncology Precision Medicine Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 13.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 13.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 13.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 13.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 13.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 13.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 13.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 13.2.3. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Oncology Precision Medicine Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Ecosystem
        • 13.3.1.2.2. By Application
    • 13.3.2. Saudi Arabia Oncology Precision Medicine Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Ecosystem
        • 13.3.2.2.2. By Application
    • 13.3.3. UAE Oncology Precision Medicine Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Ecosystem
        • 13.3.3.2.2. By Application

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. SWOT Analysis: Global Oncology Precision Medicine Market

17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)

  • 17.1. Novartis AG
  • 17.2. F. Hoffmann-La Roche AG
  • 17.3. Merck & Co., Inc.
  • 17.4. Danaher Corporation
  • 17.5. Abbott Laboratories, Inc.
  • 17.6. Quest Diagnostics Inc
  • 17.7. Eurofins Genomics LLC
  • 17.8. Laboratory Corporation of America Holdings
  • 17.9. Thermos Fischer Scientific, Inc.
  • 17.10. bioMerieux SA

18. Strategic Recommendations